AstraZeneca
oncology highlights continuing momentum across oncology with data at key medical congresses in and expanding into bladder cancer and advancing next gen and advancing with upcoming data at ash only regimen to show benefit potential new soc patients amplify fixed duration in clinically meaningful improvement trend to benefit ineligible phase next wave in house novel high rate in high levels of complete remission in good tolerability | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
November 2024
Slide
15 of 38
Related slides by other companies
MindMed
Investor Presentation
June 2023
preclinical data indicate potential enhanced benefit risk profile | MindMed
AvePoint
Investor Presentation
November 2021
why we win depth and breadth of platform approach benefits a | AvePoint
Kymera
Investor Presentation
June 2023
degraders in oncology | Kymera
Cytek
Investor Day
June 2022
advancing cell analysis with our unique technology | Cytek
Other recent decks by AstraZeneca
See all presentations (31 decks)
Results
February 2025
Results
November 2024
Investor Event
September 2024
Results
February 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io